Allogeneic bone marrow transplantation with reduced conditioning (RC-BMT)

European Journal of Haematology

Volumn 66, Issue 2, 2001, Pages 73-82

  Vindeløv, Lars ^a  

^a Tigshospitalet ^*  (Denmark)

Author keywords

Allogeneic; Bone marrow transplantation; Minitransplant; Reduced conditioning

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNE DISEASE; GENE THERAPY; GENETIC DISORDER; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NEUTROPENIA; NONHUMAN; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; STEM CELL;

BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; GRAFT SURVIVAL; GRAFT VS TUMOR EFFECT; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035121534     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2001.00354.x     Document Type: Review

References (84)

1. Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): Report of a Workshop of the European Group for Blood and Marrow Transplantation (EBMT)
2. A history of haemopoietic cell transplantation
3. Treatment of murine leukemia with X-rays and homologous bone marrow
4. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity
5. Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?
6. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect
7. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression
8. Induction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation
9. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
10. Graft-versus-leukemia reactions after bone marrow transplantation
11. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia
12. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
13. The graft-versus-leukemia effects of allogeneic cell therapy
14. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
15. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
16. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors
17. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
18. Graft-versus-myeloma effect in two cases
19. Graft-versus-myeloma effect
20. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
21. Graft-versus-myeloma effect: Proof of principle
22. Graft-versus-myeloma
23. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
24. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
25. Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: Evidence for a "graft vs. myelofibrosis" effect
26. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
27. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
28. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia
29. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma
30. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
31. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: Timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease
32. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
33. Potential allogeneic graft-versus-tumor effect in a patient with ovarian cancer
34. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
35. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for Blood and Marrow Transplantation experience
36. Treatment of chronic myeloid leukemia by marrow transplantation
37. Intensive treatment for multiple myeloma: Where do we stand?
38. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease
39. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database
40. Allogeneic bone marrow transplantation for low-grade lymphoma
41. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia
42. Bone marrow transplantation from HLA identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
43. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
44. Mixed chimerism: Preclinical studies and clinical applications
45. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation
46. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia
47. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses
48. Well-tolerated non-myeloablative fludarabine-based protocols for the treatment of malignant and non-malignant disorders with allogeneic bone marrow or blood stem cell transplantation
49. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
50. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
51. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
52. Melphalan and purine analog containing preparative regimens. Less intensive conditioning for patients with hematological malignancies undergoing allogeneic progenitor cell transplantation (PCT)
53. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
54. Mini-allografts: Ongoing trials in humans
55. Transplant-lite using fludarabine-cyclophosphamide (FC) and allogeneic stem cell transplant (alloSCT) for low-grade lymphoma (LGL)
56. Allogeneic stem cell transplantation (SCT) with fludarabine-based, less intensive conditioning as adoptive immunotherapy in advanced Hodgkin's disease (HD)
57. Reduced toxicity and transplant related mortality (TRM) following nonmyeloablative allogeneic peripheral blood stem cell transplantation for malignant disease
58. Molecular remission of chronic myelogeneous leukemia (CML): Evidence for a graft-versus-leukemia (GVL) effect following non-myeloablative allogeneic peripheral blood stem cell transplant (PBSCT)
59. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect
60. Sustained regression of metastatic renal cell carcinoma (RCC) following nonmyeloablative allogeneic peripheral blood stem cell transplantation: A new application of allogeneic immunotherapy
61. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
62. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias
63. High-intensity autotransplantation followed by reduced-intensity cytotoxic allotransplantation regimen (mini-allografting)
64. Nonmyeloablative (NMA) chemotherapy with allogeneic hematopoietic transplantation as treatment of malignancy
65. Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone
66. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation
67. Mixed lymphohematopoietic chimerism following nonmyeloablative conditioning and HLA-matched allogeneic bone marrow transplantation (BMT): The effects on chimerism and antitumor response of prophylactic donor leukocyte infusions (DLI)
68. Graft-versus-leukemia effects, mixed chimerism and early T-cell reconstitution in two patients with advanced stagechronic lymphocytic leukemia after bone marrow transplantation with a novel nonmyeloablative conditioning regimen
69. DLA-Identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment
70. Mixed chimerism: Preclinical studies and clinical applications
71. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation
72. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF)
73. Molecular remissions after non-myeloablative allografting for chronic myelocytic leukemia (CML)
74. Degree of early donor T cell chimerism predicts GVHD and graft rejection in patients with non-myeloablative hematopoietic stem cell allografts
75. Nonmyeloablative peripheral blood stem cell (PBSC) allografts following cytoreductive autotransplants for treatment of multiple myeloma (MM)
76. Hematopoietic stem cell transplants (HSCT) from HLA-matched and 1-allele mismatched unrelated donors using a nonmyeloablative regimen
77. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
78. The new immunology - The end of immunosuppressive drug therapy?
79. Transplantation of anergic histoincompatible bone marrow allografts
80. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
81. Mixed chimerism and tolerance without whole body irradiation in a large animal model
82. The future of allogeneic hematopoietic stem cell transplantation: Minimizing pain, maximizing gain
83. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting